Prognostic factors for BCLL will be ready for the clinic in the foreseeable future

被引：0

作者：

Oscier, D. ^{[1
]}

机构：

[1] Royal Bournemouth Hosp, Dept Haematol, Bournemouth BH7 7DW, Dorset, England

来源：

CYTOMETRY PART B-CLINICAL CYTOMETRY | 2007年 / 72B卷 / 02期

关键词：

D O I：

暂无

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

引用

页码：129 / 129

页数：1

共 4 条

[1] Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: Justification for risk-adapted therapy [J].

Byrd, JC ;

Gribben, JG ;

Peterson, BL ;

Grever, MR ;

Lozanski, G ;

Lucas, DM ;

Lampson, B ;

Larson, RA ;

Caligiuri, MA ;

Heerema, NA .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (03) :437-443

[2] REporting recommendations for tumour MARKer prognostic studies (REMARK) [J].

McShane L.M. ;

Altman D.G. ;

Sauerbrei W. ;

Taube S.E. ;

Gion M. ;

Clark G.M. .

British Journal of Cancer, 2005, 93 (4) :387-391

[3] Prognostic factors in the UK LRF CLL4 trial. [J].

Oscier, DG ;

Richards, S ;

Orchard, J ;

Davis, Z ;

Best, G ;

Morilla, A ;

Brito-Bapapulle, V ;

Matutes, E ;

Pettitt, A ;

Catovsky, D .

BLOOD, 2005, 106 (11) :594A-594A

[4] Risk stratification in chronic lymphocytic leukemia [J].

Seiler, T ;

Döhner, H ;

Stilgenbauer, S .

SEMINARS IN ONCOLOGY, 2006, 33 (02) :186-194

← 1 →